# Viking Therapeutics, Inc. (VKTX)

> Source: Nexqual · https://nexqual.com/VKTX · data as of 2026-11-18 18:09 UTC · cite as "Nexqual, Viking Therapeutics, Inc. (VKTX), nexqual.com/VKTX" · informational, not investment advice.

## What changed for VKTX since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Viking Therapeutics, Inc. (VKTX) stock went from USD 27.05 (close of the week of Aug 25, 2025, split-adjusted) to USD 26.91, a -0.5% price change; the S&P 500 (SPY) moved +14.9% over the same period.
- Analyst actions on VKTX in the last 120 days: 7 (3 upgrades or target raises, 3 downgrades or target cuts); most recent Canaccord Genuity, Oct 31, 2026.

**Price:** USD 26.91 (+0.11% today) · US market open, as of November 18, 2026 at 18:09 UTC; quotes may be delayed. Prev close 26.88 · day 26.26–27.36 · 52w 23.82–43.1 · market cap $3.43B · NCM

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $0K, net income -$627M (SEC filings).
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $6.3M; 3 not under a Rule 10b5-1 plan ($6.3M); 3 by opportunistic insiders (3 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.86 on a 1–5 scale) (21 analysts), mean target USD 95.32 (range 34–125).
- Total return with dividends: 1Y -28.7% vs S&P 500 +11.9%; 5Y +377.1% vs S&P 500 +66.7%.
- Latest earnings report: 2026-10-28 (next date not yet announced).
- Dividend: VKTX paid no cash dividend in the last five years.
- Short interest: 19.93% of float (as of 2026-10-30), 4.5 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | $0K | $0K |
| Operating income | -$55.7M | -$70.4M | -$101M | -$151M | -$393M | -$649M |
| Net income | -$55.0M | -$68.9M | -$85.9M | -$110M | -$360M | -$627M |
| EPS (diluted) | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 | — |
| Cash + short-term investments | $202M | $155M | $362M | $903M | $706M | — |
| Total debt | — | — | — | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/B 5.8x · Earnings yield -18.26% · Net cash $709M · EV $2.73B

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Lian Brian | President & CEO | 148,517 | $4.9M | 5.5% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-29 | Zante Greg | Chief Financial Officer | 21,217 | $710K | 9.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-29 | Mancini Marianna | Chief Operating Officer | 18,217 | $610K | 4.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 21 analysts; mean target USD 95.32 (low 34, high 125).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-31 | Canaccord Genuity | Target raised | Buy | $106 → $118 |
| 2026-10-20 | Canaccord Genuity | Target lowered | Buy | $114 → $106 |
| 2026-10-15 | UBS | Initiated | Buy | $94 |
| 2026-10-07 | Truist Securities | Target lowered | Buy | $87 → $85 |
| 2026-09-23 | Truist Securities | Target raised | Buy | $83 → $87 |
| 2026-08-11 | JP Morgan | Target lowered | Overweight | $75 → $65 |
| 2026-07-30 | Canaccord Genuity | Target raised | Buy | $107 → $114 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | -28.7% | +377.1% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -28.8% | +36.6% |
| Volatility (annualized) | 67.2% | 91.7% |
| Max drawdown | -42.5% (Jul 2026→Oct 2026) | -73.9% (Feb 2024→Apr 2025) |

## Dividends
VKTX paid no cash dividend in the last five years.

## Short interest
24,163,022 shares sold short, 19.93% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 25,921,759 shares (-6.8%). Days to cover: 4.5 (short shares ÷ average daily volume).

## Peers (Biotechnology)
MDGL (Madrigal Pharmaceuticals, Inc.) USD 406 -3.79% · SMMT (Summit Therapeutics Inc.) USD 10.62 -0.47% · TGTX (TG Therapeutics, Inc.) USD 65.87 +5.04% · KOD (Kodiak Sciences Inc) USD 96.8 -0.00% · BLTE (Belite Bio, Inc) USD 158.03 +0.20% · IBRX (ImmunityBio, Inc.) USD 6.72 +7.35%

## More
Full page: https://nexqual.com/VKTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in VKTX's own 10-K filed 2026-02-11 (https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | LIGAND PHARMACEUTICALS INC (LGND) | "We obtained exclusive worldwide rights to VK2809, VK0214 and VK5211 and certain other assets pursuant to an exclusive license agreement with Ligand Pharmaceuticals Incorporated, or Ligand." |
| Competitor | Novo Nordisk (NVO) | "VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from E…" |
| Competitor | Eli Lilly (LLY) | "VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from E…" |

## Company outlook (8-K filed 2026-10-28)

- "Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027."
- "The company expects these studies to be completed in 2027. • VANQUISH Extension Studies to Commence in 1Q27."
- "The company anticipates the results of the extension studies to be available in 2028. • SUNRISE Oral Phase 3 VK2735 Program Initiated;"
- "Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027. • Part 2 Maintenance Dosing Study Initiated, to Evaluate Oral and Additional Subcutaneous Regimens."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-1.35 | $-1.10 | −$0.25 | $0 | 18 |
| Next quarter (ends 2027-03-31) | $-1.36 | $-1.05 | −$0.31 | $0 | 7 |
| Current fiscal year (ends 2026-12-31) | $-5.31 | $-4.61 | −$0.71 | $0 | 18 |
| Next fiscal year (ends 2027-12-31) | $-5.21 | $-4.32 | −$0.89 | $0 | 18 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 89.7% | ±5.5% |
| 2026-11-27 | 9 | 75.0% | ±9.4% |
| 2026-12-04 | 16 | 72.6% | ±12.2% |
| 2026-12-11 | 23 | 70.3% | ±14.1% |
| 2026-12-18 | 30 | 66.1% | ±15.4% |
| 2026-12-24 | 36 | 54.1% | ±13.6% |
| 2026-12-31 | 43 | 53.4% | ±14.7% |
| 2027-01-15 | 58 | 68.7% | ±22.1% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Oct 28, 2026 | Quarter ended Sep 30, 2026 | −$1.55 | −$1.06 | Miss −46.2% | +7.9% |
| Jul 29, 2026 | Quarter ended Jun 30, 2026 | −$1.10 | −$1.21 | Beat +9.1% | -2.2% |
| Apr 29, 2026 | Quarter ended Mar 31, 2026 | −$1.37 | −$0.91 | Miss −50.5% | -3.7% |
| Feb 11, 2026 | Quarter ended Dec 31, 2025 | −$1.38 | −$0.90 | Miss −53.3% | +6.1% |
| Oct 22, 2025 | — | — | — | — | +2.9% |
| Jul 23, 2025 | — | — | — | — | +4.4% |
| Apr 23, 2025 | — | — | — | — | +0.7% |
| Feb 5, 2025 | — | — | — | — | -2.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-05 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 7.7% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1607678/000031506626002856/0000315066-26-002856-index.htm |
| 2026-10-29 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/0001193125-26-436432-index.htm |
| 2026-10-28 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/0001193125-26-436145-index.htm |
| 2026-09-28 | 8-K | Entered a material agreement; New debt or off-balance-sheet obligation — “Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Equity Underwriting Agreement") with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the "Equity Representatives"), as representatives of the several underwriters named therein (the "Equity Underwriters"), to issue and sell (the "Equity Offering") 7,857,143 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), at a public offering price of $35.00 per…” | https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/0001193125-26-405580-index.htm |
| 2026-09-22 | 8-K | Other material event — “On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.” | https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/0001193125-26-397219-index.htm |
| 2026-07-29 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/0001193125-26-324219-index.htm |
| 2026-07-29 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/0001193125-26-323652-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
